Ingrezza

News

The FDA has approved Neurocrine Bioscience’s Ingrezza, the first ever licensed treatment for tardive dyskinesia or TD.

Oncology

Dr Irina Babina, CEO of oncology R&D platform Concr, discusses how current regulatory frameworks were built for static diagnostics.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.